Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Selective complexation of α-amino acids and simple peptides via their carboxylate groups

Roland Schnitter , Daniel Gallego and Berthold Kersting *
Institut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany. E-mail: b.kersting@uni-leipzig.de; Fax: +49(0)341-97-36199

Received 2nd July 2014 , Accepted 29th July 2014

First published on 30th July 2014


Abstract

The complexation of anions of selected α-amino acids (alanine, valine, proline, tyrosine) and small peptides (L-alanyl-L-alanine, L-alanyl-L-alanyl-L-alanine, and L-alanyl-L-alanyl-L-alanyl-L-alanine) by the dinuclear nickel(II) complex [LNi2(μ-Cl)]+ (1), where (L)2− represents a 24-membered binucleating hexamine-dithiophenolato ligand, has been investigated. The following complexes were prepared, isolated as perchlorate or tetraphenylborate salts, and characterized by UV/Vis, IR, and CD spectroscopy: [LNi2(μ-L-alaninato)]+ (2), [LNi2(μ-L-valinato)]+ (3), [LNi2(μ-L-prolinato)]+ (4), [LNi2(μ-L-tyrosinato)]+ (5a), [LNi2(μ-D-tyrosinato)]+ (5b), [LNi2(μ-L,D-tyrosinato)]+ (5c), [LNi2(μ-L-alanyl-L-alaninato)]+ (6), [LNi2(μ-(L-alanyl)2-L-alaninato)]+ (7), [LNi2(μ-(L-alanyl)3-L-alaninato)]+ (8). Compounds 4, 5a and 6 were additionally identified by X-ray crystallography. In contrast to unsupported amino carboxylate complexes which typically contain five membered NO chelate rings, the [LNi2]2+ fragment selectively binds the α-amino acids and peptides via μ1,3-bridging carboxylato groups. Coordination of the carboxylato coligands in this way confers dissymmetry on the complexes. The CD spectra of the syn,syn-bridged structures are significantly different from those of the NO chelates, and can distinguish between the two coordination modes. The encapsulation of the peptides increases their solubility in the solvent system MeOH–MeCN by up to two orders of magnitude. This is discussed in terms of the absence of intermolecular hydrogen bonding interactions as indicated in the X-ray structure of 6.


Introduction

It is well-known that nickel(II) forms stable complexes with a range of amino acids and peptides, and that some of these complexes are of biological and technological relevance. The uptake and transport of nickel in plants, for example, is accomplished mainly by monomeric amino acids,1,2 while nickel transport in blood plasma is governed by oligopeptides.3 The molecular mechanisms of nickel toxicity appear to be associated with complexation of peptides as well.4 For instance, the N terminal XZH motif in serum albumin, which mediates transport of nickel in blood plasma, has been identified as the primary nickel binding site.5 Nickel may also bind to the octarepeat region of prion proteins and amyloid-β.6 Moreover, the affinity of nickel for the amino acid histidine is also of importance in the purification of recombinant proteins utilizing the N-terminal hexa-histidyl tag. As a consequence much interest has arisen in the coordination chemistry of nickel with amino acids and peptides,7 and a number of reviews on this topic exist.8 There is also large interest in the coordination chemistry of organometallic nickel compounds with amino acids and peptides.9

Most of the amino acids invariably bind to nickel(II) via the carboxylate-O and the amino-N donor atom, thereby forming a thermodynamically stable, five-membered chelate ring.10 The glycinato complex [Ni(gly)3] is a typical example.11 The NO chelate prevails also in a number of mixed ligand complexes,12 and in the case of amino acids with side chain donors.13–15 The O,O-(carboxylate) coordination mode with a dangling NH2 (or protonated-NH3+) function has been observed far less frequently.16 It occurs in some mono- and polynuclear lanthanide complexes,17,18 and in some dinuclear 4d and 5d metal complexes.19,20 Carboxylate-O coordination has also been observed in ternary metal complexes designed to differentiate between L and D amino acids.21 Here, the carboxylate coordination is enforced by an appended crown-ether moiety which binds the NH3+ group via three strong NH⋯O hydrogen-bonding interactions.22

The coordination modes of di-, tri-, and tetrapeptide ligands are more diverse as one might expect. In the absence of supporting ligands, the peptides generally act as chelate ligands, with a terminal N, one or more deprotonated amide ions and/or the carboxylato group.8,12 In the case of simple oligopeptides with non-coordinating side chains, complex formation with Ni(II) starts at the N-terminal end and proceeds as shown in Scheme 1.23 The affinity of Ni for dipeptide esters can be utilized in the metal-ion templated synthesis of cyclo-tetrapeptides.24


image file: c4dt02007c-s1.tif
Scheme 1 Complexation of Ni(II) by tetrapeptides.24

Our group is interested in the coordination chemistry of dinuclear nickel complexes supported by the hexaaza-dithiophenolato macrocycle (L)2− (Fig. 1).25 The macrocycle supports mixed-ligand complexes of the type [LNi2(L′)]+ with a capsular, cleft-like structure reminiscent of the “cone” conformation of the calixarenes.26 It has been established that the binding cavity influences many properties of the complexes, particularly complex stability27,28 and reactivity.29–31 Several [LNi2(μ-L′)]+ complexes with carboxylato groups (RCO2) as a coligand (L′) have been reported and crystallographically characterized.32 Besides dinuclear [LNi2(μ-O2CR)]+ structures of aliphatic and aromatic carboxylates,25 we have also reported higher-nuclearity complexes of the type [(LNi2)2(μ-O2C-R-CO2)]2+, in which pairs of bioctahedral [LNi2]2+ units are joined by a dicarboxylato dianion.33 In some of these complexes, the carboxylate ions adopt unusual conformations attributable to confinement as for instance in [LNi2(μ-3,4-dimethyl-6-phenylcyclohex-3-enecarboxylate)], where the phenyl ring and the carboxylate group both assume axial positions with respect to the cyclohexene ring.34,35


image file: c4dt02007c-f1.tif
Fig. 1 Left: Chemical formula of dinuclear [LNi2(μ-L′)]+ complexes. Right: Perspective view of the structure of carboxylato-bridged [LNi2(μ-O2CR)]+ complexes.

The high carboxylate ion affinity of the [LNi2]2+ fragment suggested that a selective coordination of amino acids and simple peptides is possible. On these grounds we synthesized and characterized a series of new [LNi2(μ-L′)]+ complexes bearing selected α-amino acids and small peptides as co-ligands (L′). Their preparation, spectroscopic properties (IR, UV/Vis, CD) and structures are reported herein.

Results and discussion

Synthesis of complexes

The α-amino carboxylato complexes 2–5 were synthesized by ligand substitution reactions from the chlorido-bridged complex 1, as it is depicted in Scheme 2. Treatment of complex 1 with a suspension of the respective α-amino acid in MeOH–MeCN in the presence of NEt3 resulted in the formation of a pale green solution, from which the corresponding [LNi2(aminocarboxylato)]+ species could be isolated as a pale-green perchlorate salt in 56–94% isolated yields. Salt metathesis of the perchlorate salts 2–5 with NaBPh4 in methanol provided the corresponding tetraphenylborate salts 2′–5′. The ESI mass spectra with a peak for the [LNi2(μ-aminocarboxylato)]+ cation and elemental analysis confirmed their constitution in each case (Table 1).
image file: c4dt02007c-s2.tif
Scheme 2 Synthesis of compounds 2–5. The corresponding tetraphenylborate salts 2′–5′ were obtained by salt metathesis with NaBPh4.
Table 1 Selected analytical data for the perchlorate (2–5) and tetraphenylborate salts (2′–5′) of the [LNi2(μ-aminocarboxylato)]+ complexes
Compd ESI-MS UV/Vis IR/cm−1 CD
m/z λ max/nm ν asym,νsymν) λ/nm (Δε/M−1 cm−1)
a MeOH–MeCN (1/2 v/v). b Solvent DMSO.
2 872.4 648, 920, 1126a 1589, 1420 (169) 422 (+0.087), 633 (+0.050), 743 (+0.022)
2′ 872.4 647, 920, 1123a 1586, 1421 (165) 424 (+0.067), 630 (+0.035), 756 (+0.012)
Alanine36 1592, 1408 (184)
3 900.4 648, 921, 1092a 1588, 1419 (169) 415 (+0.114), 632 (+0.054), 731 (+0.034)
3′ 900.5 649, 923, 1102b 1587, 1422 (165) 421 (+0.066), 629 (+0.045), 729 (+0.023)
Valine36 1575, 1424 (151)
4 898.4 639, 918, 1088a 1625, 1421 (204) 413 (+0.004), 657 (+0.004)
4′ 898.4 648, 921, 1098b 1625, 1422 (203) 412 (+0.010), 672 (+0.007)
Proline37 1619, 1402 (217)
5a 964.4 647, 921, 1127b 1593, 1420 (173) 415 (+0.099), 633 (+0.059), 735 (+0.027)
5a′ 964.4 646, 921, 1118b 1595, 1420 (175) 424 (+0.064), 628 (+0.040), 766 (+0.025)
L-Tyrosine36 1587, 1438 (149)
5b 964.4 647, 921, 1127b 1592, 1418 (174) 423 (−0.102), 624 (−0.057), 746 (−0.032)
5b′ 964.4 646, 921, 1118b 1595, 1422 (173) 424 (−0.069), 628 (−0.044), 766 (−0.023)
D-Tyrosine36 1587, 1438 (149)
5c 964.4 647, 921, 1127b 1592, 1418 (174)
5c′ 964.4 646, 921, 1118b 1593, 1422 (171)
DL-Tyrosine36 1587, 1439 (148)


All compounds are air stable in solution as well as in solid state. The perchlorate salts exhibit good solubility in polar aprotic solvents such as MeCN, CH2Cl2 and acetone (5–10 mg ml−1). They are less soluble in alcohol and virtually insoluble in water. The solubility also depends on the type of the side chain of the amino acid. Thus, compounds 2–4 bearing lipophilic side chains exhibit better solubility than 5 (with a more polar –C6H4OH group) in MeCN, while the reverse is observed in MeOH.

Characterization of the aminocarboxylato complexes

The complexes were characterized by IR, UV/Vis, and circular dichroism (CD) spectroscopy to further ascertain the formulation of the products and to establish the coordination mode of the amino acids. The IR spectra show bands arising from the [LNi2]2+ fragment, the ClO4 or BPh4 counterions, and the amino carboxylato groups. Two prominent vibrations are seen in the IR,38,39 as in other μ1,3-carboxylato-bridged Ni2 complexes of (L)2−,40,41 around 1600–1580 cm−1 (νasym(RCO2)) and 1420–1400 cm−1 (νsym(RCO2)), indicating that the amino acids are also bound in this fashion. The IR absorptions of the coordinated amino carboxylates are only slightly shifted relative to the corresponding values in their free, zwitterionic forms.36,37,42 These frequency shifts are in good agreement with coordination of the carboxylate functions. The large separation of the two carboxylate stretching modes (Δν = νasymνsym > 160 cm−1) is also in line with a bridging mode.38 The characteristic ν(NH) mode at 3300 cm−1 for the NH3+ group of free amino acids is absent in the complexes. The peaks at 3200 cm−1 correspond to the RNH2 (or R2NH (4)) groups.

Fig. 2 shows the UV/Vis spectrum of the tyrosinato complex 5a which is representative for 2–5. There are two weak absorption bands at 650 and 1100 nm attributable to the spin-allowed 3A2g3T1g (ν2) and 3A2g3T2g (ν1) transitions of a six-coordinate nickel(II) ion. The expected 3A1g3T1g(P) transition (≤450 nm) is obscured by a strong RS→NiII charge transfer transition. The shoulder at approximately 920 nm can be attributed to a spin-forbidden 3A2g1E1g(D) transition. Its observation implies a significant distortion from a pure octahedral coordination environment. Previous studies have shown that ν1 and ν2 are quite sensitive to the type of the bridging co-ligand.28 For carboxylato complexes ν1 = 1088–1028 nm and ν2 = 648–655 nm),28 very close to those of 2–5. This match in values provides strong support for a μ1,3-bridging carboxylate function.


image file: c4dt02007c-f2.tif
Fig. 2 UV/Vis spectrum of a 10−3 M solution of the L-tyrosinato complex 5a in DMSO. Inset: CD-spectra of 10−3 M solutions of the L-tyrosinato, D-tyrosinato and L,D-tyrosinato complexes 5a–5c in MeOH–MeCN (2/1) solution.

All compounds were further studied by CD spectroscopy. CD spectra were recorded from 400 to 800 nm in DMSO solution. The CD spectrum of the L-tyrosinato complex 5a (inset to Fig. 2) is again representative for all compounds.

There are two positive peaks at 633 and 743 nm which presumably correspond to the ν2 transition (at 650 nm), while the more intense peak at 422 nm is most likely a component of the ν3 and/or the charge→transfer transition. The spectrum of the D-tyrosinato complex 5b is similar to that of 5a, but the three peaks have negative values as expected from the opposite configuration of the co-ligand. The racemate 5c exhibits no net chirality, and its CD spectrum is featureless. There are not many examples in the literature to which the CD spectra of the present complexes can be compared. The spectra of octahedral [Ni(L-aminocarboxylato)2(H2O)2] complexes have been reported.43 Such compounds show two peaks for the ν2 transition as well, but they have the opposite sign. This reversal of sign is presumably associated with the different coordination modes of the amino acids. The [Ni(L-aminocarboxylato)2(H2O)2] complexes contain five-membered NO chelate rings. The puckering of the chelate rings confers dissymmetry about the metal ion and this effect contributes to the observed optical activity. In 2–5, the CD spectra arise mainly from contributions from the asymmetric C atom, due to the absence of the NO chelate rings. Therefore, by simply looking at the sign of the CD peaks, one can readily indicate the presence of a syn,syn-bridged amino-carboxylato or a NO chelate structure.

Crystal structures of the prolinato (4′) and tyrosinato complex (5a)

Crystals of 4′·2MeOH·MeCN suitable for single crystal X-ray diffraction analysis were grown from a methanol–acetonitrile solvent system. This salt crystallizes triclinic, space group P1. The crystal structure determination confirmed the presence of the carboxylato bridged [LNi2(μ-L-prolinato)]+ cation, BPh4 anions and MeOH and MeCN solvate molecules. There are two crystallographically independent but chemically identical [LNi2(μ-L-prolinato)]+ cations (molecule A and B) in the asymmetric unit. Fig. 3 shows the molecular structure of molecule A. Selected bond lengths and angles are given in the figure caption.
image file: c4dt02007c-f3.tif
Fig. 3 Structure of the [LNi2(μ-L-prolinato]+ cation (molecule A) in crystals of 4(BPh4)·2MeOH·MeCN. Thermal ellipsoids are drawn at the 50% probability level. Hydrogen atoms have been omitted for clarity, except for the NH group. Selected bond lengths/Å (values in square brackets refer to molecule B): Ni1–O1 2.009(3) [2.019(2)], Ni1–N1 2.309(3) [2.266(3)], Ni1–N2 2.145(3) [2.148(3)], Ni1–N3 2.250(4) [2.251(3)], Ni1–S1 2.4791(13) [2.5063(16)], Ni1–S2 2.4463(14) [2.4395(12)], Ni2–O2 2.026(3) [2.011(3)], Ni2–N4 2.254(3) [2.234(3)], Ni2–N5 2.142(3) [2.160(4)], Ni2–N6 2.273(3) [2.287(3)], Ni2–S1 2.4857(13) [2.4967(13)], Ni2–S2 2.4613(14) [2.4309(12)]; N7⋯O1 = 2.752 [2.748] Å.

The [LNi2]2+ unit adopts a conical “calixarene-like” conformation typical for carboxylato-bridged NiII complexes of (L)2−. The nickel(II) ions are coordinated in a square-pyramidal fashion by a fac-N3(μ-S)2 donor set. The prolinato ligand exhibits L-configuration and bridges the two six-coordinate NiII atoms in a symmetric fashion, at a Ni⋯Ni distance of 3.479(1) [3.477(1)] Å. The coordination environment of the nickel atoms is distorted octahedral, as manifested by large deviations from the ideal bond angles. The maximum deviation from the ideal angles is as large as 15.5(1)° (observed for the O(2)–Ni(2)–N(5) angle). The average Ni–N and Ni–S bond distances are 2.230(3) [2.224(3)] and 2.489(1) [2.468(1)] Å, respectively. Such bond lengths are common for bioctahedral Ni(II) complexes supported by (L)2−.25 The average Ni–O bond lengths are at 2.013(2) [2.016(3)] Å. Similar values are observed in other carboxylato-bridged [LNi2(μ-O2CR)]+ complexes indicating that the amino acids bind equally well to the dinuclear [LNi2]2+ fragment.

The crystal structure of the L-tyrosinato complex 5a was characterized by X-ray crystallography using crystals of 5a·2.25MeCN. The crystal structure comprises dinuclear [LNi2(μ-L-tyrosinato)]+ cations, perchlorate anions, and acetonitrile solvate molecules. There are two crystallographically independent [LNi2(μ-L-tyrosinato)]+ cations in the asymmetric unit, which differ slightly structurally as detailed below. The tyrosinato-complex (Fig. 4) is isostructural with the prolinato complex, with the tyrosinato ligand being coordinated in a bidentate bridging mode and the supporting ligand adopting the bowl-shaped “cone” conformation. Each cation is also connected to a ClO4 anion by an intermolecular hydrogen bond involving the phenolic OH group of the tyrosinato ligand (not shown in Fig. 4).


image file: c4dt02007c-f4.tif
Fig. 4 Structure of the [LNi2(μ-L-tyrosinato]+ cation (left molecule A, right molecule B) in crystals of 5a·2.25MeCN. Thermal ellipsoids are drawn at the 50% probability level. Hydrogen atoms have been omitted for clarity, except for NH2 groups. Selected bond lengths/Å (values in square brackets refer to molecule B): Ni1–O1 2.008(3) [2.014(3)], Ni1–N1 2.275(4) [2.270(3)], Ni1–N2 2.148(3) [2.140(3)], Ni1–N3 2.255(3) [2.260(3)], Ni1–S1 2.502(1) [2.467(1)], Ni1–S2 2.470(1) [2.486(1)], Ni2–O2 2.021(3) [1.999(3)], Ni2–N4 2.238(4) [2.260(3)], Ni2–N5 2.141(3) [2.137(3)], Ni2–N6 2.290(3) [2.240(4)], Ni2–S1 2.449(1) [2.487(1)], Ni2–S2 2.466(1) [2.467(1)]; N7a⋯O2a 2.742 Å, N7b⋯O2b 2.717.

As mentioned above there are two [LNi2(μ-L-tyrosinato)]+ cations in the asymmetric unit, and their structures differ slightly. In molecule “A” the NH2 group and the CH2C6H4OH side chain are located on different sides of the plane through the carboxylato group. In molecule “B” the two groups are on the same side of the carboxylato plane (the CHNH2CH2C6H4OH group is rotated counter-clockwise by ∼45° about the O2C–CHNH2R bond). The occurrence of these two orientations can be traced to the presence of the intramolecular NH⋯O hydrogen bonding interactions involving the NH2 and the carboxylato group (the NH2 hydrogen atoms were located in the final Fourier map). The absence of the third possible orientation, in which the H and the CH2C6H4OH groups are on the same side of the carboxylato plane (and in which the NH2 group is more remote from the O atoms thereby disfavouring the hydrogen bond) supports this assumption.

Synthesis of peptide complexes

The selective complexation of the amino acids prompted us to investigate the possible complexation of small peptides via their C-terminal carboxylate function. The three peptides (L-alanyl)n-L-alanine (n = 1–3) were selected as they contain no side chains with potential donor atoms which would presumably interact with another [LNi2]2+ fragment. The reactions were performed in analogy to the synthesis of the amino carboxylate complexes above (Scheme 3). Thus, a suspension containing [LNi2(μ-Cl)](ClO4) and the respective peptide was stirred in MeOH–MeCN in the presence of NEt3 for 4 h to give a pale green solution, from which upon addition of an excess of LiClO4 the corresponding [LNi2(peptide)]+ complexes could be isolated as perchlorate salts 6–8 in 84–95% isolated yields. Salt metathesis of these with NaBPh4 in MeOH furnished the corresponding tetraphenylborate salts 6′–8′. The di-, tri-, and tetrapeptides react essentially in the same fashion as the amino carboxylates producing dinuclear mixed-ligand [LNi2(μ-peptide)]+ complexes with analogous structures in similar good yields and reaction times.
image file: c4dt02007c-s3.tif
Scheme 3 Synthesis of the perchlorate salts 6–8. The corresponding tetraphenylborate salts 6′–8′ were obtained by salt metathesis of 6–8 with NaBPh4.

The perchlorate salts 6–8 are air stable in solution as well as in solid state. They exhibit good solubility in polar aprotic solvents such as MeCN, CH2Cl2 and acetone. They are less soluble in alcohol and virtually insoluble in water. Again, the solubility of compounds 6–8 was found to be dependent on the length of the peptide chain, similar to the side-chain dependence in case of the amino carboxylate complexes above. Thus, compound 8 is more soluble in methanol than 6. In addition the complexes are more soluble than the free peptides. In MeOH–MeCN (2[thin space (1/6-em)]:[thin space (1/6-em)]1) the solubilities are 1.30 × 10−3 mol l−1 for (L-alanyl)-L-alanine, 0.65 × 10−3 mol l−1 for (L-alanyl)2-L-alanine, and 0.22 × 10−3 mol l−1 (L-alanyl)3-L-alanine. The perchlorate salts of the complexes are up to two orders of magnitude more soluble in the same solvent system (6: 5.83 × 10−3 mol l−1, 7: 7.33 × 10−3 mol l−1, 8: 16.08 × 10−3 mol l−1). This is attributed to the partial encapsulation of the peptides in the binding pocket of [LNi2]2+ which hinders the formation of intermolecular hydrogen-bonding interaction which would otherwise lead to an extended network as present in the free peptides (Fig. 5).44–47 It is assumed that part of the peptide chain is still exposed to the solvent medium, given that the binding pocket of the [LNi2]2+ unit has a depth of not more than ∼6 Å. This would explain why the solubility increases with the length of the peptide chain.


image file: c4dt02007c-f5.tif
Fig. 5 Left: Intermolecular hydrogen bonding interactions in (L-alanyl)2-L-alanine leading to a β-sheet.46 Right: α-Helix from intramolecular interaction in (L-alanyl)3-L-alanine.47

Characterization of the peptide complexes

The peptide complexes were characterized by elemental analyses, ESI-MS, IR, UV/Vis and CD spectroscopy. Table 2 lists selected data.
Table 2 Selected analytical data for the ClO4 and BPh4 salts of complexes 6–8
Compd ESI-MS UV/Vis IR, ν/cm−1 CD
m/z λ max/nm ν asym, vs(RCO2) (Δν);ν(CONH), δ(NH) λ/nm (Δε/M−1 cm−1)
a MeCN. b IR (KBr).
6 943.3 648, 910, 1115a 1603, 1417 (186); 1662, 1507 421 (+0.060), 627 (+0.036), 756 (+0.013)
6′ 943.3 649, 918, 1116 1602, 1420 (182); —, 1670
(L-Alanyl)-L-Alanineb 1607, 1404 (203)
1685, 1560
7 1014.4 650, 912, 1115a 1605, 1418 (187); 1676, 1489 421 (+0.065), 637 (+0.043), 762 (+0.051)
7′ 1014.3 649, 918, 1113 1605, 1425 (180); 1676, 1483
(L-Alanyl)2-L-Alanineb 1595, 1428 (187)
1649, 1528
8 1085.4 645, 909, 1106a 1605, 1418 (187); 1671, 1491 420 (+0.068), 633 (+0.052), 755 (+0.055)
8′ 1085.4 640, 917, 1110 1607, 1424 (183); 1668, 1482
(L-Alanyl)3-L-Alanineb 1603, 1404 (199)
1633, 1540


The characterization data for the L-alanyl-L-alaninato complex 6 are representative. The electrospray ionization mass spectrum (ESI-MS) of a dilute methanol solution of 6 (ESI) showed only two predominant peaks, corresponding to [LNi2(μ-L-alanyl-L-alaninato)]+ (m/z = 945.3) and [LNi2]2+ (m/z = 392.2), and the elemental analysis agreed well with the formulation of a 1[thin space (1/6-em)]:[thin space (1/6-em)]1 complex. The IR spectrum of 6 revealed two characteristic absorptions for a μ1,3-bridging carboxylate function at 1603 cm−1 (νasym(RCO2)) and 1417 cm−1 (νsym(RCO2)) (Fig. 6), as well as bands at 1100 and 625 cm−1 for the ClO4 ion. Another characteristic feature of the IR spectra is the amide I stretching mode,48 associated mainly with the C[double bond, length as m-dash]O group from the peptide backbone (Fig. 6). The frequency of this vibration is highly affected by structural changes associated to the loss or formation of hydrogen bonds which define the secondary structure of peptides.49–52 A comparison of the IR spectra of L-alanyl-L-alanine and 6 shows that the amide I stretch is shifted by 23 cm−1 to lower energy, while for complexes 7 and 8 a hypsochromic shift by 27 and 35 cm−1 is observed. The shift to higher energy of the amide I vibration mode indicates a structural change which is believed to be a consequence of the encapsulation and the concomitant loss of intermolecular hydrogen bonds seen in the free peptides. The crystal structure of complex 6′ described below also supports this assumption.


image file: c4dt02007c-f6.tif
Fig. 6 IR spectra of compounds 6–8 (KBR pellets) in the 1800–1200 cm−1 region.

The electronic absorption spectrum of 6 is very similar to that of 2 (Fig. 7), even the shoulder at 910 nm for the spin-forbidden 3A2g1Eg(D) transition is observed, again indicative of a distorted octahedral NiN3S2Ocarboxylato chromophore in 6. However, the spin-allowed 3A2g3T1g transition (a measure of the octahedral splitting parameter Δo)53 at 1114 nm is slightly blue-shifted relative to 2 suggesting that the L-alanyl-L-alaninato ligand exerts a slightly stronger ligand field than the L-alaninato ligand. This may be traced to a weaker hydrogen-bonding interaction between the amide NH and the carboxylato-group, such that the latter is more basic in the dipeptide and in turn the stronger ligand (the same applies to the tri and tetrapeptides in 7 and 8, respectively). The 3A1g3T2g transitions appear to be not dependent on the type of the coligand, as they scatter randomly between 646 and 650 nm. The 3A1g3T1g(P) transition is again obscured by strong RS→NiII charge transfer transitions below 450 nm.


image file: c4dt02007c-f7.tif
Fig. 7 UV/Vis and CD spectra (inset) of 10−3 M solutions of the perchlorate salts 6–8 in CH3CN at room temperature.

The inset to Fig. 7 shows the CD spectrum of 6. Again, the spectrum is similar to that of 2 showing two positive peaks at 626 and 759 nm which correspond to the ν2 transition (at 650 nm), and a peak at 418 nm assumed to be a component of the ν3 (or the charge→transfer) transition. Overall, the spectroscopic similarities to the amino-carboxylato complexes provide strong support for a carboxylate-coordination of the peptide coligands.

Description of the crystal structure of the L-alanyl-L-alaninato complex 6′·2MeCN

We have not been able to grow single crystals of the tri- and tetrapeptide complexes 7 and 8 yet. However, in case of the L-alanyl-L-alaninato complex 6, single crystals could be grown. The X-ray crystallographic analyses of the tetraphenylborate salt [LNi2(μ-L-alanyl-L-alaninato)]BPh4·2MeCN (6′·2MeCN) unambiguously confirmed the presence of a μ1,3-bridging (L)-alanyl-L-alaninato coligand (Fig. 8). The asymmetric unit contains two crystallographically independent but chemically identical [LNi2(μ-L-alanyl-L-alaninato)]+ cations, two BPh4 anions and four acetonitrile solvate molecules. Besides the presence of the O,O-carboxylato coordination there are three significant structural differences from the free peptide:44,45 (a) the absence of intermolecular H-bonding interaction of the L-alanyl-L-alaninato coligand, (b) the strong departure from a fully stretched peptide chain (i.e. the C43–N8 and the C42–N7 bonds are cis while they are trans in L-alanyl-L-alanine,44,45 and (c) the presence of a bifurcated hydrogen bonding interaction of the amide NH donor with the carboxylato-O and the N-terminal NH2 group. All these observations can be traced to the encapsulation of the dipeptide, which protects it from the surrounding medium. Such a protecting effect has not been observed previously for the [LNi2]2+ fragment. However, it is known that confinement in the binding pocket can lead to unusual conformations of the coligand. The other structural features in 6′ are normal. The average Ni–N, Ni–S and Ni–O bond lengths are at 2.247(8), 2.487(3), and 2.015(6) Å, respectively. The Ni⋯Ni distance is 3.496(1) [3.499(1)] Å in 6. Virtually the same values are seen in 4a and 5.
image file: c4dt02007c-f8.tif
Fig. 8 Structure of the [LNi2(μ-L-alanyl-L-alaninato)]+ cation (molecule A) in crystals of 6′·2MeCN. Thermal ellipsoids are drawn at the 50% probability level. Hydrogen atoms have been omitted for clarity, except for those of the peptide coligand. Selected bond lengths/Å (values in square brackets refer to molecule B): Ni1–O1 2.027(6) [2.015(7)], Ni1–N1 2.326(8) [2.301(7)], Ni1–N2 2.182(8) [2.136(8)], Ni1–N3 2.258(7) [2.283(9)], Ni1–S1 2.504(3) [2.492(3)], Ni1–S2 2.460(3) [2.494(3)], Ni2–O2 2.006(5) [2.010(7)], Ni2–N4 2.306(7) [2.320(8)], Ni2–N5 2.160(7) [2.146(8)], Ni2–N6 2.262(7) [2.280(8)], Ni2–S1 2.505(3) [2.490(3)], Ni2–S2 2.480(3) [2.471(3)]; N7⋯N8 2.766 [2.638], N7⋯O3 2.250 [2.279].

Conclusion

Seven new macrocyclic complexes of the type [LNi2(μ-O2CR)]+ containing the anions of various α-aminoacids and oligopeptides as coligands were synthesized by reacting [LNi2(μ-Cl)]ClO4 (1) with the corresponding coligand in methanol solution, namely [LNi2(μ-L-alaninato)]+ (2), [LNi2(μ-L-valinato)]+ (3), [LNi2(μ-L-prolinato)]+ (4), [LNi2(μ-L-tyrosinato)]+ (5a), [LNi2(μ-D-tyrosinato)]+ (5b), [LNi2(μ-L,D-tyrosinato)]+ (5c), [LNi2(μ-L-alanyl-L-alaninato)]+ (6), [LNi2(μ-(L-alanyl)2-L-alaninato)]+ (7), and [LNi2(μ-(L-alanyl)3-L-alaninato)]+ (8). The reaction yields appear to be not dependent on the chain length of the aminoacids or peptide. The complexes differ from other amino carboxylato structures in that they are selectively bound via their carboxylate groups and not as NO chelates. From IR spectra there is evidence about structural changes along the peptide backbone upon coordination to the dinuclear complex fragment. This fact is supported by the crystal structure of complex 6′ which reveals three major structural differences between the bound and the free dipeptide coligand. The solubility of the complexed oligopeptides is also altered upon coordination, which can be traced to the loss of intermolecular hydrogen bonding interactions upon encapsulation. The CD spectra of the syn,syn-bridged structures are significantly different from those of the NO chelates, and can distinguish between the two coordination modes. These results can now be used as a guide for the complexation of other oligopeptides.

Experimental section

General methods and instrumentation

IR spectra were recorded on a Bruker TENSOR 27 FT-IR-spectrometer. Electronic absorption spectra were recorded on a JASCO V670 UV/vis/NIR spectrometer. Elemental analyzes were carried out with a VARIO EL elemental analyzer. Compounds were dried under high vacuum for eight hours. Circular dichroism spectra were recorded on a JASCO J-715 spectropolarimeter. Mass spectra were taken on a BRUKER ESQUIRE 3000 PLUS instrument. Solvents and reagent were used in reagent purity. Amino acids from Alfa Aesar (D-, D/L-, L-tyrosine) and Sigma Aldrich (L-alanine, L-proline, L-valine) were optically pure and used without further purification. The syntheses of the metal complexes were carried out under a protective atmosphere of argon using standard Schlenk techniques. Starting Materials. Complex [LNi2(μ-Cl)](ClO4) (1) was prepared according to the literature procedure.40 All other reagents were obtained from standard commercial sources and used without further purification.

Safety Note! Perchlorate complexes are potentially explosive, and caution should be exercised when such derivatives are handled. However, the small quantities used in this study were not found to present a hazard. In our laboratory, small quantities of perchlorate complexes are routinely tested for their explosive potential by controlled mechanical impact.54

General procedure for the preparation of the carboxylato-bridged nickel(II) complexes 2–5. Perchlorate salts: [LNi2(μ-L′)](ClO4). To a solution of the chlorido-bridged complex 1 (92 mg, 0.10 mmol) in MeOH–MeCN (2[thin space (1/6-em)]:[thin space (1/6-em)]1) (30 mL) was added a suspension of the amino acid HL′ (0.10 mmol) in 5 mL of same solvent system, followed by 14 μL (0.10 mmol) of triethylamine. The mixture was stirred for 4 h to give a green solution. A solution of LiClO4·3H2O (0.16 g, 1.00 mmol) in EtOH (5 mL) was added. The solution was concentrated by evaporation at 40 °C to a volume of about 5 mL until incipient precipitation, and was then allowed to stand for another 6 h. The crude product was filtered, purified by recrystallization from a mixed MeCN–EtOH (1[thin space (1/6-em)]:[thin space (1/6-em)]1) solvent system, and dried under high vacuum for eight hours. Tetraphenylborate salts: The tetraphenylborate salts [LNi2(μ-L′)](BPh4) were obtained as green powders by adding a solution of NaBPh4 (342 mg, 1.00 mmol) in EtOH (5 mL) to a solution of [LNi2(μ-L′)](ClO4) (0.10 mmol) in MeOH–MeCN (2[thin space (1/6-em)]:[thin space (1/6-em)]1) (30 mL). The crude product was filtered, purified by recrystallization from a mixed MeCN–EtOH (1[thin space (1/6-em)]:[thin space (1/6-em)]1) solvent system, and dried in vacuo.

Characterization data. [LNi2(μ-L-alaninato)](ClO4) (2). Yield: 87 mg (89 μmol, 91%). IR (KBr): ν/cm−1 = 2962 s, 2893 sh, 2868 s, 2806 m, 1589 s (νas(RCO2)), 1459 vs, 1420 m (νsymm(RCO2)), 1170 w, 1153 m, 1097 vs, 1080 vs, 1061 s, 1041 s, 931 m, 752 w, 625 s. UV/Vis (MeOH–MeCN 2[thin space (1/6-em)]:[thin space (1/6-em)]1): λmax/nm (ε/M−1 cm−1) = 648 (20), 920sh, 1126 (58). MS (ESI+): m/z = 872.4 ([M − ClO4]+, 83%). Elemental analysis for C41H70ClN7Ni2O6S2 (974.01); C 50.11 (calc. 50.56), H 7.30 (7.24), N 9.79 (10.07) %.
[LNi2(μ-L-alaninato)](BPh4) (2′). Yield: 82 mg (69 μmol, 69%). IR (KBr), ν/cm−1: 3033 m, 2963 s, 2867 s, 1586 s (νas(RCO2)), 1460 vs, 1421 m (νsymm(RCO2)), 733 s, 704 vs, 627 w, 612 s. UV/Vis (MeOH–MeCN 2[thin space (1/6-em)]:[thin space (1/6-em)]1): λmax/nm (ε/M−1 cm−1): 647 (24), 920sh, 1123 (62). MS (ESI+): m/z = 872.4 ([M − BPh4]+, 90%). Elemental analysis for C65H90BN7Ni2O2S2·H2O (1193.78 + 18.02): C 64.35 (calc. 64.42), H 7.49 (7.65), N 8.05 (8.09).
[LNi2(μ-L-valinato](ClO4) (3). Yield: 56 mg (56 μmol, 56%). IR (KBr), ν/cm−1: 2964 s, 2871 s, 1588 s (νas(RCO2)), 1486 m, 1463 s, 1419 m (νsymm(RCO2)), 1379 w, 1363 m, 1151 m, 1102 vs, 1039 vs, 930 w, 754 w, 626 s. UV/Vis (MeOH–MeCN 2[thin space (1/6-em)]:[thin space (1/6-em)]1): λmax/nm (ε/M−1 cm−1) = 648 (30), 921sh, 1092 (67). MS (ESI+): m/z = 900.4 ([M − ClO4]+, 92%). Elemental analysis for C43H75ClN7Ni2O6S2·HClO4·H2O (1002.06 + 18.02): C 50.61 (calc. 50.63), H 7.41 (7.51), N 9.56 (9.61).
[LNi2(μ-L-valinato](BPh4) (3′). Yield: 121 mg (99 μmol, 99%). IR(KBr): 3054 m, 3034 m, 2999 m, 2982 m, 2963 s, 2927 m, 2901 m, 2867 s, 1587 s (νas(RCO2)), 1579 m, 1479 s, 1459 vs, 1422 s (νsymm(RCO2)), 1396 m, 1362 m, 748 m, 734 s, 705 vs, 628 m, 612 m. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 454sh, 649 (24), 923sh, 1102 (57). MS (ESI+): m/z = 900.5 ([M − BPh4]+, 89%). Elemental analysis for C67H94BN7Ni2O2S2 (1221.84): C 65.79 (calc. 65.86), H 7.63 (7.75), N 7.93 (8.02).
[LNi2(μ-L-prolinato](ClO4) (4). Yield: 94 mg (94 μmol, 94%). IR (KBr), ν/cm−1: 2962 s, 2901 s, 2869 s, 2807 m, 1625 s (νas(RCO2)), 1462 s, 1421 m (νsymm(RCO2)), 1396 m, 1363 m, 1153 m, 1100 vs, 1077 vs, 1038 s, 930 m, 754 w, 625 s. UV/Vis (MeOH–MeCN 2[thin space (1/6-em)]:[thin space (1/6-em)]1): λmax/nm (ε/M−1 cm−1) = 639 (58), 918sh, 1088 nm (79). MS (ESI+): m/z = 898.4 (M − ClO4, 98%). Elemental analysis for C43H72ClN7Ni2O6S2·H2O (1000.05 + 18.02): C 50.64 (calc. 50.73); H 7.21 (7.33); N 9.49 (9.63).
[LNi2(μ-L-prolinato)](BPh4) (4′). Yield: 121 mg (99 μmol, 99%). IR(KBr): 3056 m, 3034 m, 3014 m, 2999 m, 2984 s, 2963 s, 2930 m, 2899 m, 2877 m, 1625 s (νas(RCO2)), 1579 m, 1480 s, 1462 vs, 1450 vs, 1422 m (νsymm(RCO2)), 1393 m, 1363 m, 753 s, 734 vs, 710 vs, 627 w, 612 s. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 453sh, 648 (24), 921sh, 1098 nm (57). MS (ESI+): m/z = 898.4 (M+ − BPh4, 40%). Elemental analysis for C67H92BN7Ni2O2S2 (1219.82): C 65.79 (calc. 65.97), H 7.63 (7.60), N 7.93 (8.04).
[LNi2(μ-L-tyrosinato](ClO4) (5a). Yield: 86 mg (81 μmol, 81%). IR (KBr), ν/cm−1: 2960 s, 2899 s, 2869 s, 2807 m, 1593 s (νas(RCO2)), 1516 s, 1485 m, 1462 vs, 1420 s (νsymm(RCO2)), 1395 m, 1363 m, 1171 w, 1152 m, 1102 vs, 1077 vs, 1058 vs, 1041 s, 930 m, 752 w, 627 m., 1462 s, 1420 m, 1396 m, 1363 m, 1153 m, 1100 vs, 1077 vs, 1038 s, 930 m, 754 w, 625 s. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 647 (25), 921sh, 1127 (60). MS (ESI+): m/z = 964.4 (M+ − ClO4, 93%). Elemental analysis for C47H74ClN7Ni2O7S2 H2O (1067.11 + 18.02): C 51.88 (calc. 52.07), H 6.91 (7.07), N 9.01 (9.04).
[LNi2(μ-L-tyrosinato](BPh4) (5a′). Yield: 127 mg (99 μmol, 99%). IR (KBr): 3053 s, 3036 m, 2998 s, 2982 s, 2964 s, 2925 m, 2898 m, 2864 s, 2807 m, 2612 w, 1595 s (νas(RCO2)), 1585 m, 1476 s, 1459 s, 1420 m (νsymm(RCO2)), 1392 m, 1363 m, 774 w, 737 s, 705 vs, 629 m, 610 m. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 450sh, 646 (22), 921sh, 1118 nm (51). MS (ESI+): m/z = 964.3 (M+ − ClO4, 95%). Elemental analysis for C67H92BN7Ni2O2S2 (1285.88 + 18.02): C 65.28 (calc. 65.40), H 7.31 (7.42), N 7.40 (7.52).
[LNi2(μ-D-tyrosinato)](ClO4) (5b). Yield: 90 mg (84 μmol, 84%). IR (KBr), ν/cm−1: 2960 s, 2899 s, 2869 s, 2807 m, 1592 s (νas(RCO2)), 1516 s, 1485 m, 1462 vs, 1418 m (νsymm(RCO2)), 1395 m, 1363 m, 1171 w, 1152 m, 1102 vs, 1077 vs, 1058 vs, 1041 s, 930 m, 752 w, 627 m, 1462 s, 1420 m, 1396 m, 1363 m, 1153 m, 1100 vs, 1077 vs, 1038 s, 930 m, 754 w, 625 s. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 647 (25), 921sh, 1127 nm (60). MS (ESI+): m/z = 964.4 (M+ − ClO4, 93%). Elemental analysis for C47H74ClN7Ni2O7S2·H2O (1084.12): C 51.95 (calc. 52.07), H 6.97 (7.07), N 8.96 (9.04).
[LNi2(μ-D-tyrosinato)](BPh4) (5b′). Yield: 90 mg (90 μmol, 90%). IR (KBr): ν/cm−1 = 3053 s, 3036 m, 2998 s, 2982 s, 2964 s, 2925 m, 2898 m, 2864 s, 2807 m, 2612 w, 1593 s (νas(RCO2)), 1585 m, 1476 s, 1459 s, 1422 w (νsymm(RCO2)), 1392 m, 1363 m, 774 w, 737 s, 705 vs, 629 m, 610 m. UV/Vis (DMSO: λmax/nm (ε/M−1 cm−1) = 450sh, 646 (22), 921sh, 1118 (51). MS (ESI+): m/z = 964.3 (M+ − ClO4, 95%). Elemental analysis for C71H94BN7Ni2O3S2 H2O (1285.88 + 18.02): C 65.33 (calc. 65.40), H 7.36 (7.42), N 7.44 (7.52).
[LNi2(μ-D/L-tyrosinato)](ClO4) (5c). Yield: 62 mg (58 μmol, 58%). IR (KBr), ν/cm−1: 2960 s, 2899 s, 2869 s, 2807 m, 1592 s (νas(RCO2)), 1516 s, 1485 m, 1462 vs, 1418 m (νsymm(RCO2)), 1395 m, 1363 m, 1171 w, 1152 m, 1102 vs, 1077 vs, 1058 vs, 1041 s, 930 m, 752 w, 627 m., 1462 s, 1420 m, 1396 m, 1363 m, 1153 m, 1100 vs, 1077 vs, 1038 s, 930 m, 754 w, 625 s. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 647 (25), 921sh, 1127 nm (60). MS (ESI+): m/z = 964.4 (M+ − ClO4, 93%). Elemental analysis for C47H74ClN7Ni2O7S2·H2O (1084.12): C 51.92 (calc. 52.07), H 7.01 (7.07), N 8.98 (9.04).
[LNi(μ-D/L-tyrosinato)](BPh4) (5c′). 105 mg (82 μmol, 82%). IR (KBr): 3053 s, 3036 m, 2998 s, 2982 s, 2964 s, 2925 m, 2898 m, 2864 s, 2807 m, 2612 w, 1593 s (νas(RCO2)), 1585 m, 1476 s, 1459 s, 1422 m (νsymm (RCO2)), 1392 m, 1363 m, 774 w, 737 s, 705 vs, 629 m, 610 m. UV/Vis (DMSO): λmax/nm (ε/M−1 cm−1) = 450sh, 646 (22), 921sh, 1118 nm (51). MS (ESI+): m/z = 964.3 (M+ − ClO4, 95%). Elemental analysis for C71H94BN7Ni2O3S2·H2O (1285.88 + 18.02): C 65.32 (calc. 65.40), H 7.37 (7.42), N 7.43 (7.52).
[LNi2(μ-L-alanyl-L-alaninato)](ClO4) (6). Yield: 99 mg (95 μmol, 95%). IR (KBr): ν/cm−1: 2963, 2902, 2869 s (ν(C–H)), 1662 m (ν(C[double bond, length as m-dash]O, amide I)), 1603 vs (νas(RCO2)), 1507 m (δ(N–H, amide II)), 1458 vs (δsciss(CH2)/δ(CH3)), 1417 m (νs(RCO2)), 1097 vs b (ν(Cl–O)), 623 m (δ(ClO4)). UV-Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 646 (45), 910sh, 1114 (70). MS (ESI+): m/z = 943.4 (M+ − ClO4, 98%). Elemental analysis for C44H75ClN8Ni2O7S2·4H2O (1045.09 + 72.06): C 47.14 (calc. 47.31), H 7.40 (7.49), N 10.30 (10.03), S 5.44 (5.74).
[LNi2(μ-L-alanyl-L-alaninato)](BPh4) (6′). Yield: 99 mg (78 μmol, 78%). IR (KBr): ν/cm−1: 3397 m (ν(N–H)), 3054 m, 3033 m (ν(C–H arom.)), 2963 s, 2868 s (ν(C–H aliph.)), 1670 s (ν(C[double bond, length as m-dash]O amide I)), 1602 vs (νasym(CO2)), 1581 m (ν(C[double bond, length as m-dash]C arom.)), 1458 vs (δsciss (CH2)/δ(CH3)), 1420 m (νs(RCO2)), 733 s, 705 vs (BPh4). UV-Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 649 (29), 918 sh, 1116 (72). MS (ESI+): m/z = 943.3 (M+ − BPh4, 97%). Elemental analysis for C68H95BN8Ni2O3S2·EtOH2 (1264.86 + 92.14): C 63.76 (calc. 63.73), H 7.51 (7.95), N 8.42 (8.26).
[LNi2(μ-L-alanyl-L-alanyl-L-alaninato)](ClO4) (7). Yield: 103 mg (92 μmol, 92%). IR (KBr): ν/cm−1: 3425 s (ν(O–H assoc.)), 2963 s, 2869 s (ν(C–H)), 1676 s (ν(C[double bond, length as m-dash]O, amide I)), 1605 vs (νas(RCO2)), 1489 s (δ(N–H, amide II)), 1459 vs (δsciss(CH2)/δ(CH3)), 1418 m (νs (RCO2), 1098 vs b (ν(Cl–O)), 624 m (δ(ClO4)). UV-Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 650 (25), 910sh, 1115 (62). MS (ESI+): m/z = 1014.4 (M+ − ClO4, 96%). Elemental analysis for C47H80ClN9Ni2O8S2(H2O)3 (1116.17 + 54.03): C 48.28 (calc. 48.24), H 7.48 (7.41), N 9.64 (10.77), S 5.70 (5.48).
[LNi2(μ-L-alanyl-L-alanyl-L-alaninato)](BPh4) (7′). Yield: 103 mg (77 μmol, 77%). IR (KBr) ν/cm−1: 3424 vs b (ν(O–H)), 3055 m, 3034 m (ν (C–H arom.)), 2964 s, 2869 s (ν(C–H aliph.)), 1676 s (ν(C[double bond, length as m-dash]O amide I)), 1605 vs (νas (RCO2)), 1581 m (ν(C[double bond, length as m-dash]C arom.)), 1483 s (δ(N–H, amide II)), 1458 vs (δsciss(CH2)/δ(CH3)), 1425 m (νs (RCO2)), 734 vs, 705 vs (BPh4). UV-Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 649 (31), 918 sh 1113 (72). MS (ESI+) m/z (MeCN): 1014.3 (M+ − BPh4, 98%). UV-Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 640 (61), 917 sh, 1110 (72). Elemental analysis for C71H100BN9Ni2O4S2·2EtOH (1335.96 + 92.14): C 64.37 (calc. 63.08), H 7.57 (7.91), N 8.63 (8.83).
[LNi2(μ-L-alanyl-L-alanyl-L-alanyl-L-alaninato)](ClO4) (8). Yield: 100 mg (84 μmol, 84%); IR (KBr) ν/cm−1: 3423 s (ν(N–H)), 2964 s, 2870 s (ν(C–H)), 1671 s (ν(C[double bond, length as m-dash]O, amide I)), 1605 vs (νas(RCO2)), 1491 s (δ (N–H, amide II)), 1457 vs (δsciss (CH2)/δ (CH3)), 1418 m (νs(RCO2)), 1107 vs b (ν(Cl–O)), 625 m (δ(ClO4)). UV-Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 645 sh, 909sh 1106 (76). MS (ESI): m/z (MeCN): 1085.4 (M+ − ClO4). Elemental analysis for C50H85ClN10Ni2O9S2·3H2O (1187.25 + 54.05): C 48.41 (calc. 48.38), H 7.58 (7.39), N 10.88 (11.28), S 5.14 (5.17).
[LNi2(μ-L-alanyl-L-alanyl-L-alanyl-L-alaninato)](BPh4) (8′). Yield: 101 mg (72 μmol, 72%). IR (KBr) ν/cm−1: 3416 s b (ν(O–H)), 3055 m, 3035 m (ν(C–H arom.)), 2965 s, 2869 s (ν(C–H aliph.)), 1668 s (ν(C[double bond, length as m-dash]O amide I)), 1607 vs (νas(RCO2)), 1581 m (ν(C[double bond, length as m-dash]C arom.)), 1482 s (δ(N–H, amide II)), 1458 vs (δsciss (CH2)/δ (CH3)), 1424 m (νs(RCO2)), 735 vs, 706 vs (BPh4). MS (ESI+): m/z (MeCN): 1085.4 (M+ − BPh4, 95%). UV/Vis (MeCN): λmax/nm (ε/M−1 cm−1) = 640 (61.4), 917sh, 1110 (72.0). Elemental analysis for C74H105BN10Ni2O5S2·H2O (1407.04 + 18.02): C 62.43 (calc. 62.37), H 7.68 (7.57), N 9.68 (9.83).

Crystallography

The data sets for 4′ 2MeOH·MeCN, 5a·2.5MeCN and 6′·2MeCN were collected using a Bruker SMART CCD diffractometer equipped with graphite monochromated Mo-Kα radiation (0.71073 Å). The data were processed with SAINT and corrected for absorption using SADABS.55 Structures were solved by Direct Methods56 and refined by full-matrix least-squares on the basis of all data against F2 using SHELXL-97.57 PLATON was used to search for higher symmetry.58 Ortep3 was used for the artwork of the structures.59 Unless otherwise noted the anisotropic thermal parameters of all non-hydrogen atoms were refined. H atoms were placed at calculated positions and refined as riding atoms with isotropic displacement parameters. All non-hydrogen atoms were refined anisotropically. CCDC 982688 (4′·2MeOH·MeCN), CCDC 982689 (5a·2.25MeCN) and CCDC 1011258 (6′·2MeCN) contain the supplementary crystallographic data for this paper.
Crystal data for 4′·2MeOH·MeCN. C71H103BN8Ni2O4S2, M = 1324.96 g mol−1, triclinic space group P1, a = 15.245(3), b = 16.340(3), c = 16.867(3) Å, α = 116.77(3), β = 105.89(3), γ = 95.67(3)°, V = 3485.2(11) Å3, Z = 2 (two crystallographically independent but chemically identical molecules A and B in the asymmetric unit), Dc = 1.263 g cm−3, μ = 0.653 mm−1, 22[thin space (1/6-em)]331 reflections collected, 18[thin space (1/6-em)]759 unique (Rint = 0.0154). The MeOH and MeCN are heavily disordered, and the electron density associated to these molecules was removed from the structure (and the corresponding Fo) with the SQUEEZE procedure implemented in the PLATON program suite.60 Final R1 [F2 > 2σ(F2)] = 0.0347 (R1 = 0.0419 before SQUEEZE), wR2 (all data) = 0.1016, R1 index based on 18[thin space (1/6-em)]759 reflections with I > 2σ(I) (refinement on F2). Flack x = 0.033(8). The H atom bonded to the secondary N atom of the prolinato ligand was located from a final Fourier map but was not refined. One tert-butyl group was found to be disordered over two positions. A split atom model was applied using the SADI instructions implemented in SHELXL to account for this disorder (C36B-C38B/C36C-C38C). The site occupancies (0.26/0.74) were refined.
Crystal data for 5a·2.5MeCN. C51.50H80.75ClN9.25Ni2O7S2, M = 1158.49 g mol−1, triclinic space group P1, a = 14.0485(4), b = 15.2778(4), c = 16.2737(3) Å, α = 113.857(2), β = 97.723(2), γ = 111.779(2)°, V = 2795.05(12) Å3, Z = 2 (two crystallographically independent but chemically identical molecules A and B in the asymmetric unit), Dc = 1.377 g cm−3, μ = 0.854 mm−1, 48[thin space (1/6-em)]198 reflections collected, 26[thin space (1/6-em)]658 unique (Rint = 0.0375). Final R1 [F2 > 2σ(F2)] = 0.0348, wR2 (all data) = 0.0949, R1 index based on 22[thin space (1/6-em)]501 reflections with I > 2σ(I) (refinement on F2). Flack x = 0.039(9).
Crystal data for 6′·2MeCN. C72H101BN10Ni2O3S2, M = 1346.98 g mol−1, triclinic space group P1, a = 14.872(3), b = 16.889(3), c = 17.068(3) Å, α = 97.83(3), β = 105.66(3), γ = 115.48(3)°, V = 3566.0(12) Å3, Z = 2 (two crystallographically independent but chemically identical molecules A and B in the asymmetric unit), Dc = 1.254 g cm−3, μ = 0.639 mm−1, 25[thin space (1/6-em)]832 reflections collected, 23[thin space (1/6-em)]850 unique (Rint = 0.0731). Final R1 [F2 > 2σ(F2)] = 0.0339, wR2 (all data) = 0.0722, R1 index based on 22[thin space (1/6-em)]501 reflections with I > 2σ(I) (refinement on F2). Flack x = 0.005(15). All MeCN solvate molecules were refined isotropically.

Acknowledgements

We are grateful to Prof. Dr E.-M. Hey-Hawkins and Prof. Dr A.-B. Sickinger for providing facilities for X-ray crystallographic and CD spectroscopic measurements.

References

  1. D. A. Cataldo, K. M. McFadden, T. R. Garland and R. E. Wildung, Plant Physiol., 1988, 86, 734–739 CrossRef CAS PubMed.
  2. U. Krämer, J. D. Cotterhowells, J. M. Charnock, A. J. M. Baker and J. A. C. Smith, Nature, 1996, 379, 635–638 CrossRef.
  3. S. Sagner, R. Kneer, G. Wanner, J. P. Cosson, B. Deus-Neumann and M. H. Zenk, Phytochemistry, 1998, 47, 339–347 CrossRef CAS.
  4. J. P. Laussac and B. Sarkar, Biochemistry, 1984, 23, 2832–2838 CrossRef CAS.
  5. J. D. Glennon and B. Sarkar, Biochem. J., 1982, 203, 15–23 CAS.
  6. M. Klewpatinond, P. Davies, S. Bowen, D. R. Brown and J. H. Viles, J. Biol. Chem., 2008, 283, 1870–1881 CrossRef CAS PubMed.
  7. R. P. Bonomo, D. La Mendola, G. Pappalardo, E. Rizzarelli and I. Sóvágó, in Recent Development in Bioinorganic Chemistry: Metal Complexes of Bioactive Molecules, ed. M. Saviano, Transworld Research Network, India, 2006, pp. 133–160 Search PubMed.
  8. (a) H. Sigel and R. B. Martin, Chem. Rev., 1982, 82, 385–426 CrossRef CAS; (b) R. B. Martin, Nickel Binding to Amino Acids and Peptides, in Metal Ions in Biological Systems, ed. A. Sigel and H. Sigel, vol. 23, 1988, pp. 123–164 Search PubMed; (c) F. Meyer and H. Kozlowski, in Comprehensive Coordination Chemistry II, ed. J. A. McCleverty and T. J. Meyer, Elsevier, vol. 6, 2004, pp. 247–554 Search PubMed; (d) T. Kowalik-Jankowska, H. Kozlowski, E. Farkas and I. Sóvágó, Met. Ions Life Sci., 2007, 2, 63–108 CAS.
  9. (a) K. Severin, R. Bergs and W. Beck, Angew. Chem., Int. Ed., 1998, 110, 1722–1743 ( Angew. Chem. Int. Ed. , 1998 , 37 , 1634–1654 ) CrossRef; (b) D. R. van Staveren and N. Metzler-Nolte, Chem. Rev., 2004, 104, 5931–5985 CrossRef CAS PubMed.
  10. (a) J. E. Letter Jr. and John E. Baumann Jr., J. Am. Chem. Soc., 1970, 92, 437–442 CrossRef; (b) T. B. Freedmann, D. A. Young, M. R. Oboodi and L. A. Nafie, J. Am. Chem. Soc., 1987, 109, 1551–1559 CrossRef.
  11. H. Irving and R. J. P. Williams, Nature, 1948, 162, 746–747 CrossRef CAS.
  12. E. Farkas and I. Sovago, Amino Acids, Pept., Proteins, 2007, 36, 287–345 CAS.
  13. I. Sóvágó and K. Ősz, Dalton Trans., 2006, 3841–3854 Search PubMed.
  14. Y. Shimazaki, M. Takani and O. Yamauchi, Dalton Trans., 2009, 7854–7869 RSC.
  15. D. K. Nayak, K. K. Halder, R. Baishya, T. Sen, P. Mitrac and M. C. Debnath, Dalton Trans., 2013, 42, 13565–13575 RSC.
  16. N. Burford, M. D. Eelman, W. G. LeBlanc, T. S. Cameron and K. N. Robertson, Chem. Commun., 2004, 332–333 RSC.
  17. (a) I. Csöreg, P. Kierkegaard, J. Legendziewicz and E. Huskowska, Acta Chem. Scand., 1987, A41, 453–460 CrossRef PubMed; (b) I. Csöreg, P. Kierkegaard, J. Legendziewicz and E. Huskowska, Acta Chem. Scand., 1989, A43, 636–640 CrossRef PubMed; (c) Q. Jin, X. Wang, T. Jin and G. Xu, Polyhedron, 1994, 13, 2957–2961 CrossRef CAS.
  18. J. J. Zhang, T. L. Sheng, S. Q. Xia, G. Leibeling, F. Meyer, S. M. Hu, R. B. Fu, S. C. Xiang and X. T. Wu, Inorg. Chem., 2004, 43, 5472–5478 CrossRef CAS PubMed.
  19. J. Frelek, A. Klimek and P. Ruskowska, Curr. Org. Chem., 2003, 7, 1081–1104 CrossRef CAS.
  20. I. R. Baird, B. R. Cameron and R. T. Skerlj, Inorg. Chim. Acta, 2003, 353, 107–118 CrossRef CAS.
  21. H. Tsukube, M. Wada, S. Shinoda and H. Tamiaki, Chem. Commun., 1999, 1007–1008 RSC.
  22. B. Korybut-Daszkiewicz, J. Taraszewska, K. Zieba, A. Makal and K. Wozniak, Eur. J. Inorg. Chem., 2004, 3335–3344 CrossRef CAS PubMed.
  23. F. Meyer and H. Kozlowski, ChemInform, 2004, 35, 247–554 Search PubMed.
  24. J. Schapp, K. Haas, K. Sünkel and W. Beck, Eur. J. Inorg. Chem., 2003, 3745 CrossRef CAS PubMed.
  25. V. Lozan, C. Loose, J. Kortus and B. Kersting, Coord. Chem. Rev., 2009, 253, 2244–2260 CrossRef CAS PubMed.
  26. C. D. Gutsche Calixarenes revisited, in Monographs in Supramolecular Chemistry, ed. J. F. Stoddart, Royal Society of Chemistry, Cambridge, 1998 Search PubMed.
  27. V. Lozan and B. Kersting, Inorg. Chem., 2008, 47, 5386–5393 CrossRef CAS PubMed.
  28. U. Lehmann, J. Klingele, V. Lozan, G. Steinfeld, M. H. Klingele, S. Käss, A. Rodenstein and B. Kersting, Inorg. Chem., 2010, 49, 11018–11029 CrossRef CAS PubMed.
  29. B. Kersting, in Activating Unreactive Molecules – The Role of secondary Interactions, ed. C. Bolm and F. E. Hahn, Wiley-VCH, Weinheim, 2009, ch. 1, pp. 1–17 Search PubMed.
  30. B. Kersting and U. Lehmann, Adv. Inorg. Chem., 2009, 61, 407–470 CrossRef CAS , (ed. R. v. Eldik and C. D. Hubbard).
  31. J. Lach, A. Jeremies, V. Lozan, C. Loose, T. Hahn, J. Kortus and B. Kersting, Inorg. Chem., 2012, 51, 12380–12388 CrossRef CAS PubMed.
  32. T. Glaser, Y. Journaux, G. Steinfeld, V. Lozan and B. Kersting, Dalton Trans., 2006, 1738–1748 Search PubMed.
  33. J. Klingele, M. H. Klingele, O. Baars, V. Lozan, A. Buchholz, G. Leibeling, W. Plass, F. Meyer and B. Kersting, Eur. J. Inorg. Chem., 2007, 5277–5285 CrossRef CAS PubMed.
  34. S. Käss and B. Kersting, Eur. J. Inorg. Chem., 2012, 2389–2401 CrossRef PubMed.
  35. S. Käss, T. Gregor and B. Kersting, Angew. Chem., 2006, 118, 107–110 ( Angew. Chem., Int. Ed. , 2006 , 45 , 101–104 ) CrossRef PubMed.
  36. R. J. Koegel, J. P. Greenstein, M. Winitz, S. M. Birnbaum and R. A. McCallum, J. Am. Chem. Soc., 1955, 77, 5708–5720 CrossRef CAS.
  37. A. W. Herlinger and T. V. Long II, J. Am. Chem. Soc., 1970, 92, 6481–6486 CrossRef CAS.
  38. K. Nakamoto, Infrared and Raman Spectra of Inorganic and Coordination Compounds, Wiley, New York, 5th edn, 1997 Search PubMed.
  39. G. B. Deacon and R. J. Phillips, Coord. Chem. Rev., 1980, 33, 227–250 CrossRef CAS.
  40. B. Kersting, Angew. Chem., 2001, 113, 4110–4112 ( Angew. Chem., Int Ed. , 2001 , 40 , 3987–3990 ) CrossRef.
  41. J. Hausmann, M. H. Klingele, V. Lozan, G. Steinfled, D. Siebert, Y. Journaux, J. J. Girerd and B. Kersting, Chem. – Eur. J., 2004, 10, 1716–1728 CrossRef CAS PubMed.
  42. A. R. Garcia, R. B. de Barros, J. P. Loureno and L. M. Ilharco, J. Phys. Chem. A, 2008, 112, 8280–8287 CrossRef CAS PubMed.
  43. R. A. Haines and M. Reimer, Inorg. Chem., 1973, 12, 1482–1486 CrossRef CAS.
  44. R. J. Fletterick, C.-C. Tsai and R. E. Hughes, J. Phys. Chem., 1971, 75, 918–922 CrossRef CAS.
  45. Y. Tokuma, T. Ashida and M. Kakudo, Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem., 1969, 25, 1367–1374 CrossRef CAS.
  46. A. Hempel, N. Camerman and A. Camerman, Biopolymers, 1991, 31, 187–192 CrossRef CAS PubMed.
  47. S. Krimm, Biopolymers, 1983, 22, 217–225 CrossRef CAS PubMed.
  48. J. Bandekar, Biochim. Biophys. Acta, 1992, 1120, 123–143 CrossRef CAS.
  49. (a) W. C. Reisdorf, Jr. and S. Krimm, Biochem., 1996, 35, 1383–1386 CrossRef PubMed; (b) L. Wang, C. T. Middleton, M. T. Zanni and J. L. Skinner, J. Phys. Chem., 2011, B115, 3713–3724 Search PubMed.
  50. J. W. Brauner, C. Dugan and R. Mendelsohn, J. Am. Chem. Soc., 2000, 122, 677–683 CrossRef CAS.
  51. R. Schweitzer-Stenner, Vib. Spectrosc., 2006, 42, 98–117 CrossRef CAS PubMed.
  52. (a) J. Grdadolnik, S. G. Grdadolnik and F. Avbelj, J. Phys. Chem. B, 2008, 112, 2712–2718 CrossRef CAS PubMed; (b) N. G. Mirkin and S. Krimm, J. Phys. Chem. A, 2002, 106, 3391–3394 CrossRef CAS.
  53. A. B. P. Lever, Inorganic Electron Spectroscopy, Elsevier Science, Amsterdam, 2nd edn, 1984 Search PubMed.
  54. M. J. MacLachlan, M. K. Park and L. K. Thompson, Inorg. Chem., 1996, 35, 5492–5499 CrossRef CAS PubMed.
  55. SADABS, An empirical absorption correction program part ot the SAINTPlus NT version 5.10 package, BRUKER AXS, Madison, WI, 1998 Search PubMed.
  56. G. M. Sheldrick, Acta Crystallogr., Sect. A: Fundam. Crystallogr., 1990, 46, 467–473 CrossRef.
  57. G. M. Sheldrick, SHELXL-97, Computer program for crystal structure refinement, University of Göttingen, Göttingen, Germany, 1997 Search PubMed.
  58. A. L. Spek, PLATON – A Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The Netherlands, 2000 Search PubMed.
  59. L. J. Farrugia, J. Appl. Crystallogr., 1997, 30, 565 CrossRef CAS.
  60. P. v. d. Sluis and A. L. Spek, Acta Crystallogr., Sect. A: Fundam. Crystallogr., 1990, 46, 194 CrossRef.

Footnote

Electronic supplementary information (ESI) available. CCDC 982688, 982689 and 1011258. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4dt02007c

This journal is © The Royal Society of Chemistry 2014